Want to see DRIO full AI Analyst Report?
DRIO Stock Chart & Stats
$11.72
-$0.63(-41.18%)
At close: 4:00 PM EST
$11.72
-$0.63(-41.18%)
Day’s Range― - ―
52-Week Range$5.84 - $17.74
Previous CloseN/A
Volume780.96K
Average Volume (3M)33.32K
Market Cap
$49.50M
Enterprise Value$64.34
Total Cash (Recent Filing)$20.26M
Total Debt (Recent Filing)$31.82M
Price to Earnings (P/E)2.0
Beta0.53
Next Earnings
Aug 17, 2026EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.33
Shares Outstanding7,312,398
10 Day Avg. Volume41,359
30 Day Avg. Volume33,324
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)8.32
Price to Sales (P/S)25.26
P/FCF Ratio-21.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.50Price Target Upside-10.41% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.71
Revenue Forecast (FY)$26.16M
Bulls Say, Bears Say
Bulls Say
High B2B2C Gross MarginsSustained ~80% non-GAAP B2B2C gross margins indicate durable unit economics for channel sales. High incremental margins reduce capital intensity for growth, allow profitable scale once fixed costs are absorbed, and support reinvestment into product and partnerships without high per-user cost pressure.
Large Commercial Pipeline And DistributionA sizable $127M pipeline and steady account wins give the company optionality to convert recurring revenue over 2026–2027. Combined with expanding partner reach, this provides a scalable route to membership growth and recurring contract exposure that can amplify margins as channel deployments standardize.
Proprietary Data And AI-driven EngagementExtensive data assets and clinical evidence create a defensible differentiation for personalization and outcomes-based contracting. DarioIQ engagement lifts (better retention and session activity) imply higher lifetime value and stronger case for payers/providers to adopt long-term contracts tied to measurable outcomes.
Bears Say
Persistent Negative Operating Cash FlowOngoing negative operating and free cash flow signals continued cash burn and reliance on external funding or balance-sheet resources. This constrains the pace of commercial investment, risks dilution or higher financing costs, and may limit the company's ability to fund large partner implementations if conversions slip.
Operating Losses & Earnings-quality ConcernsMaterial GAAP and non‑GAAP operating losses despite an unusual TTM net income swing point to earnings-quality issues. Without sustained operating profitability, scaling revenue may not translate to durable earnings, keeping returns volatile and limiting flexibility for long-term strategic investments.
Timing And Channel-conversion RiskHeavy dependence on partner-driven conversions and large deployments creates structural timing risk: implementation, eligibility and technical integration delays can push revenue and cash realization, making growth lumpy and increasing execution risk as the company scales channel-based contracts.
DarioHealth News
DRIO FAQ
What was DarioHealth Corp’s price range in the past 12 months?
DarioHealth Corp lowest stock price was $5.84 and its highest was $17.74 in the past 12 months.
What is DarioHealth Corp’s market cap?
DarioHealth Corp’s market cap is $49.50M.
When is DarioHealth Corp’s upcoming earnings report date?
DarioHealth Corp’s upcoming earnings report date is Aug 17, 2026 which is in 25 days.
How were DarioHealth Corp’s earnings last quarter?
DarioHealth Corp released its earnings results on May 13, 2026. The company reported -$1.25 earnings per share for the quarter, beating the consensus estimate of -$1.48 by $0.23.
Is DarioHealth Corp overvalued?
According to Wall Street analysts DarioHealth Corp’s price is currently Overvalued.
Does DarioHealth Corp pay dividends?
DarioHealth Corp does not currently pay dividends.
What is DarioHealth Corp’s EPS estimate?
DarioHealth Corp’s EPS estimate is -1.22.
How many shares outstanding does DarioHealth Corp have?
DarioHealth Corp has 7,312,398 shares outstanding.
What happened to DarioHealth Corp’s price movement after its last earnings report?
DarioHealth Corp reported an EPS of -$1.25 in its last earnings report, beating expectations of -$1.48. Following the earnings report the stock price went down -6.682%.
Which hedge fund is a major shareholder of DarioHealth Corp?
Currently, no hedge funds are holding shares in DRIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DarioHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (-10.41% Downside)
$10.50 (-10.41% Downside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.66%
Trailing 12-Months
Company Description
DarioHealth Corp
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
DRIO Stock 12 Month Forecast
Average Price Target
$10.50
▼(-10.41% Downside)
Technical Analysis
Ownership Overview
7.32% Insiders
1.60% Mutual Funds
8.36% Other Institutional Investors
81.56% Public Companies and
Individual Investors